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Recent studies underscore that chronic hypoxia in the
tubulointerstitium is a final common pathway to progression
to end-stage renal failure regardless of etiology. We used
microarray analysis of rat kidneys made hypoxic by unilateral
renal artery stenosis to measure transcriptomic events and
clarify pathophysiological mechanisms of renal injury
induced by chronic hypoxia. Many genes were upregulated
in the kidney by chronic hypoxia, but we focused on
metallothionein due to its antioxidative properties. Using
tubular epithelial cells transfected with a reporter construct
of luciferase, driven by the hypoxia-responsive elements
(HRE), we found that addition of metallothionein to the
culture media increased luciferase activity. This was
associated with upregulation of the target genes of
hypoxia-inducible factor (HIF), such as vascular endothelial
growth factor and glucose transporter-1. Stimulation of the
HIF-HRE pathway by metallothionein was confirmed by
metallothionein overexpression. Hypoxia and exogenous
metallothionein increased HIF-1a protein without changes
in its mRNA levels, suggesting protein stabilization.
Upregulation of the HIF-HRE system by metallothionein was
associated with phosphorylation of ERK but not Akt. MEK
inhibition and rapamycin decreased metallothionein-induced
HIF activity. Our study shows that upregulation of
metallothionein expression by hypoxia activates the HIF-HRE
system through the ERK/mTOR pathway and may be a novel
defense against hypoxia.
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Chronic hypoxia of the kidney has been implicated in
the pathogenesis and progression of chronic kidney disease
regardless of the underlying disease.1–3 Cellular responses
to oxygen are important in many aspects of physiological
homeostasis and have been a hot topic in a wide
range of fields. However, the underlying pathophysiology
of the kidney in chronic hypoxia has not been fully
understood.
Many previous studies demonstrated chronic hypoxia
in the kidney of a variety of models, including the
remnant kidney,4,5 chronic progressive glomerulonephritis,6,7
puromycin nephrosis,8 diabetic nephropathy,9 cisplatin
nephropathy,10 and aging kidney.11 However, kidneys of
these models are confounded by nonhypoxic factors
such as proteinuria and hyperglycemia. Recent studies
utilizing blood oxygenation level-dependent magnetic reso-
nance imaging (BOLD MRI) suggested that stenotic kidney
reveals continuous and progressive hypoxia.12 Although
reduction of renal blood flow can also activate fibrogenic
or vasoactive pathways, which modulate cytokines and
inflammatory mediators, we employed renal artery
stenosis, most common form of ischemic nephropathy,
as a model of hypoxic nephropathy in the current study.
To clarify a molecular pathogenesis of renal injury induced by
chronic hypoxia we decided to perform microarray analysis
employing a model of chronic renal artery stenosis. We
selected the time points of relatively early stages, days 3 and 7,
because we wanted to exclude a potential contribution of
nonspecific effects of secondary changes induced by tubu-
lointerstitial damage due to not only hypoxia but other
factors such as inflammation and apoptosis as much as
possible.
Among the genes upregulated in the stenotic kidney,
we focused on metallothionein (MT), which is involved
in metal detoxification and also functions as an antioxidant,
and examined biological functions of MT in hypoxia.
In in vitro studies, we found that MT activates the
hypoxia-inducible factor (HIF)/hypoxia-responsive element
(HRE) pathway. This activation of the HIF–HRE system by
MT was associated with phosphorylation of extracellular
signal-regulated kinase (ERK).
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RESULTS
Microarray analysis revealed modified expression of various
genes
Of 15,924 genes displayed on the microarray, we observed
expression of 5124 genes under the basal conditions of
normal rats. A total of 88 genes were induced over twofold
change in the stenotic kidney at 3 days, and 120 genes were
upregulated over twofold change at 7 days after induction of
renal artery stenosis (Table 1). On the other hand, 26 and 48
genes were suppressed under 0.5-fold change at days 3 and 7,
respectively. Expression patterns of 96 genes were consistently
altered following renal artery stenosis, including 77 genes that
Table 1 | Non-EST genes increased over twofold change at both days 3 and 7
Fold change in mRNA levels
GenBank accession Gene Day 3 Day 7
Inflammatory mediators and immunological modulators
AB001382 Osteopontin 12.5 17.7
AF314657 Clusterin 6.58 12.3
NM_016994 Complement component 3 (C3) 3.53 3.90
AW434057 Complement component 1, q subcomponent, b-polypeptide 2.83 4.37
BI285347 Complement component 4 (C4) 4.15 11.7
AJ249701 MHC class Ia A2q antigen (RT1-A2q gene) 2.78 3.79
L40362 MHC class I RT1.C-type protein 4.38 13.9
BM389513 MHC class II antigen RT1.B-b chain 2.90 3.55
BI285141 CD24 antigen 2.29 2.74
NM_134390 TORID 2.00 2.52
Growth factors and related proteins
AA818262 Angiopoietin-like protein 4 (ANGPTL4) 10.0 15.7
NM_013144 Insulin-like growth factor binding protein 1 (IGFBP1) 4.40 3.14
Metal binding proteins
AF202115 GPI-anchored ceruloplasmin 2.42 4.74
NM_012532 Ceruloplasmin (ferroxidase) (Cp) 3.55 5.76
AA945178 Transferrin 2.39 5.95
AF411318 Metallothionein 1 4.81 3.51
BM383531 Metallothionein 2 3.03 3.20
Kinases
NM_053887 Mitogen-activated protein kinase kinase kinase 1 (Map3k1) 2.20 4.36
D64048 Phosphatidylinositol 3-kinase p45 subunit 2.00 3.70
Proteases and protease inhibitors
J02941 Renin 3.85 2.02
X83537 Membrane-type matrix metalloproteinase 3.11 3.02
NM_013128 Carboxypeptidase E (Cpe) 2.59 4.76
NM_024400 A disintegrin and metalloproteinase with
thrombospondin motifs 1 (ADAMTS-1)
4.83 5.79
NM_017320 Cathepsin S (Ctss) 2.58 3.39
NM_053819 Tissue inhibitor of metalloproteinase 1 (Timp1) 3.30 3.72
NM_031531 Serine protease inhibitor (Spin2c) 2.04 10.4
Oxidases and reductases
NM_022278 Glutaredoxin 1 (thioltransferase) (Glrx1) 2.98 3.89
Other enzymes
AF394783 Sulfotransferase SULT1A1 2.54 3.22
NM_012930 Carnitine palmitoyltransferase 2 (Cpt2) 2.51 2.00
NM_022393 Macrophage galactose N-acetyl-galactosamine-specific lectin (Mgl) 11.5 24.6
L12458 Lysozyme gene 2.07 3.03
Receptors
NM_013091 Tumor necrosis factor receptor superfamily, member 1a (Tnfrsf1a) 2.02 2.48
Transporters
NM_053380 Solute carrier family 34 (sodium phosphate), member 2 (Slc34a2) 5.22 7.34
Adhesion molecules
NM_031700 Claudin 3 (Cldn3) 5.12 11.6
NM_012967 Intercellular adhesion molecule 1 (Icam1) 3.14 2.76
NM_019195 Integrin-associated protein (Itgp) 2.32 3.36
Kidney International (2009) 75, 268–277 269
I Kojima et al.: Metallothionein in hypoxia and HIF in the kidney o r i g i n a l a r t i c l e
were upregulated over twofold and 19 genes downregulated
under 0.5-fold at both periods examined. The identified
genes are tabulated in Tables 1 and 2. Among the genes that
displayed consistent changes in expression on the micro-
arrays at days 3 and 7, 30 were expressed sequence tags. The
effect of chronic hypoxia was observed in various classes of
genes, including inflammatory mediators, growth factors,
and adhesion molecules. Among them were genes previously
implicated in the pathogenesis of ischemic injury (for
example, intercellular adhesion molecule-1 and kidney injury
molecule (KIM)-1).
Validation of the microarray analysis by real-time
quantitative PCR analysis
To rule out artifacts in microarray analysis, we validated
upregulation of five genes utilizing real-time quantitative
reverse transcriptase-PCR (RT-PCR) analysis. We selected
ceruloplasmin, insulin-like growth factor binding protein 1
(IGFBP1), angiopoietin-like protein 4 (ANGPTL4), KIM-1,
and lipocalin 2 (NGAL) as the representative five genes
because previous studies suggested crucial regulation of their
products in hypoxic condition. The results of quantitative
RT-PCR analysis were consistent with the changes detected
by microarray analysis (Table 3).
Increased mRNA levels of MTs in chronic hypoxic kidneys and
hypoxic cultured tubular cells
Among the genes modified by chronic hypoxia in the kidney,
we decided to focus on MTs because MTs protect cells against
oxidative stress. Our microarray analysis revealed that MT-1
was increased by 4.81-fold at 3 days and 3.51-fold at 7 days,
and MT-2 was increased by 3.03- and 3.20-fold, respectively,
in the hypoxic kidneys (Table 1). To verify these results above,
we performed real-time quantitative RT-PCR analysis. The
expression of MT-1 estimated by quantitative RT-PCR
analysis significantly rose to 19.39±4.52-fold at 3 days and
6.79±1.63-fold at 7 days, and MT-2 rose to 8.39±1.67- and
4.52±0.75-fold, respectively, in the hypoxic kidneys. We next
measured expression of MT-1 and MT-2 in cultured tubular
cells after hypoxic stimulation. Tubular cells were cultured in
1% O2 for 24 h. Our real-time PCR demonstrated that MT-1
mRNA expression increased to 1.55-fold (n¼ 6 each,
Po0.05) whereas that of MT-2 increased to 1.25-fold
(n¼ 6 each, P¼ 0.45) by the hypoxic exposure (Figure 1).
These findings showed that hypoxia upregulates the expres-
sion of MT mRNA both in vivo and in vitro.
MT was predominantly increased in the proximal tubules of
chronic hypoxic kidneys
We performed immunohistochemical staining of MT.
Staining of MT in tubules of the normal kidney was very
faint, and glomeruli were negative (Figure 2a). We observed
upregulation of MT in the proximal tubules at 3 days after
induction of hypoxia (Figure 2b). The increased staining
persisted at 7 days after the induction (Figure 2c). We also
performed an antibody absorption test using the monoclonal
antibody preincubated with MT, and observed no positive
staining (Figure 2d). These results were also confirmed by
western blot analysis, which demonstrated that chronic
ischemia increased MT protein levels (fivefold at 3 days
Table 1 | Continued
Fold change in mRNA levels
GenBank accession Gene Day 3 Day 7
Transcription factors
NM_012551 Early growth response 1 (Egr1) 4.16 3.31
NM_024125 Liver-activating protein (LAP, also NF-IL6, nuclear factor-IL6,
previously designated TCF5) (Cebpb)
3.85 3.12
Immediate early genes
NM_017259 Early induced gene, B-cell translocation gene 2 (Btg2) 2.93 2.21
AB025017 TIS11 2.28 2.00
Others
NM_130741 Rattus norvegicus lipocalin 2 (Lcn2) (NGAL) 6.13 9.22
AF035963 Kidney injury molecule-1 (KIM-1) 5.27 4.40
NM_053538 Lysosomal-associated protein transmembrane 5 (Laptm5) 2.00 2.10
NM_022849 CRP-ductin (Crpd) 2.42 2.70
NM_080906 HIF-1 responsive RTP801 (Rtp801) 2.14 2.13
NM_133298 Glycoprotein (transmembrane) nmb (Gpnmb) 6.63 6.31
NM_019354 Uncoupling protein 2, mitochondrial (Ucp2) 2.94 3.08
M33648 Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 3.11 2.89
U30789 Clone N27 2.00 2.45
BM386384 Nucleosome assembly protein 1-like 1 2.78 2.93
BG378926 Ribosomal protein L21 2.41 3.59
NM_031114 Lectin, galactose binding, soluble 3 (Lgals3) 3.10 3.19
NM_022278 S-100-related protein, clone 42C (S100A10) 2.33 2.54
BI288701 B-cell translocation gene 2, antiproliferative 2.55 2.07
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and threefold at 7 days) compared with normal kidneys
(Figure 2e).
A proinflammatory factor or oxidative stress was not
responsible for MT upregulation
As upregulation of MT in the stenotic kidney might be
affected by other confounding factors such as inflammation
and oxidative stress, we investigated in vitro changes in MT
expression by addition of tumor-necrosis factor-a (TNF-a) as
a proinflammatory cytokine or hydrogen peroxide as a source
of oxidative stress. Although addition of zinc as a positive
control markedly increased MT expression, TNF-a and
hydrogen peroxide failed to induce any changes in MT
expression (Figure 3).
MT enhanced activation of the HIF–HRE pathway in both
normoxic and hypoxic conditions
To evaluate effects of MT on HIF activation, we measured
luciferase (LUC) activity controlled by HRE in HRE-LUC-
immortalized rat proximal tubular cell (IRPTC). Enhancement
of HIF activation by MT was observed in a dose-dependent
manner under the hypoxic condition (control:
374,909±14,254, MT 250 nM: 630,266±8215, MT 1250 nM:
1,119,243±34,000, n¼ 3 each) (Figure 4a). LUC activity was
also increased by MT stimulation under the normoxic
condition (control: 237,019±12,167, MT 250 nM: 286,820±
10,063, MT 1250 nM: 314,803±9593, n¼ 3 each). Next, in
order to confirm the HIF–HRE pathway activation, we
examined the target genes of HIF–HRE systems, vascular
endothelial growth factor, Glut-1, and HO-1. MT stimulation
increased mRNA levels of these genes both under normoxic
and hypoxic conditions. Fold increases of each mRNA
expression compared with control were 2.23±0.09-,
3.17±0.24-, and 3.47±0.22-fold, respectively, under nor-
moxia (n¼ 6 each). Under hypoxia, those compared with
Table 3 | Validation of the expression patterns obtained from
microarrays with quantitative real-time PCR
Gene Day 3 Day 7
Ceruloplasmin 3.21±0.52 5.77±0.73
IGFBP1 4.19±0.36 2.71±0.29
ANGPTL 4 34.87±6.93 52.51±8.23
KIM-1 56.48±22.38 47.51±11.80
NGAL 23.14±11.23 33.53±5.62
IGFBP1, insulin-like growth factor binding protein 1; ANGPTL4, angiopoietin-like
protein 4; KIM-1, kidney injury molecule-1; NGAL, Rattus norvegicus lipocalin 2.
Data are presented by mean±s.e.m. (n=5 each).
Table 2 | Non-EST genes suppressed under 0.5-fold change at both days 3 and 7
Fold change in mRNA levels
GenBank accession Gene Day 3 Day 7
Growth factors
NM_012842 Epidermal growth factor 0.49 0.32
Mediators of oxidative stress
NM_053524 NADPH oxidase 4 (Nox4) 0.49 0.19
Proteases and nucleases
NM_013097 Deoxyribonuclease I (Dnase1) 0.28 0.19
Receptors
BF417032 Transferrin receptor 0.45 0.40
Transporters
D50306 Proton-coupled dipeptide cotransporter 0.40 0.33
X97445 Monocarboxylate transporter MCT2 0.41 0.27
Others
NM_031841 Stearoyl-coenzyme A desaturase 2 (Scd2) 0.30 0.28
AF158248 Vanilloid receptor splice variant 0.36 0.44
NM_134418 Secretory (zymogen) granule membrane glycoprotein GP2 (Gp2) 0.42 0.37
NM_133547 Sulfotransferase family, cytosolic, 1C, member 2 (Sult1c2) 0.48 0.39
NM_013042 Trefoil factor (intestinal) (Tff3) 0.37 0.40
AF189724 Stromal cell-derived factor-1a 0.48 0.44
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Figure 1 | Upregulation of MT by hypoxia. Proximal tubular cells
were cultured in 1% O2 for 24 h. Quantitative real-time PCR
demonstrated that hypoxia upregulated MT-1 mRNA expression
significantly, whereas MT-2 mRNA did not change (P¼ 0.45).
*Po0.05 versus normoxic control.
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those of hypoxic baseline were also 1.82±0.11-, 1.87±0.08-,
and 1.34±0.06-fold, respectively (n¼ 6 each) (Figure 4b).
To verify the results above, we performed quantitative RT-
PCR and western blot analysis of HIF-1a. Neither hypoxia
nor MT stimulation increased mRNA levels of HIF-1a, but
both of them increased the protein level of HIF-1a, which
demonstrated that not only hypoxic stimulation but also MT
stimulation stabilized the HIF-1a protein (Figure 5a and b).
Overexpression of MTs also activated the HIF–HRE pathway
To rule out an artifact of contamination in the MT reagent,
we further analyzed HEK293T transiently transfected with a
vector plasmid of MTs. At 36 h after the transfection, LUC
activities of human MT-1 and human MT-2-transfected
HRE-LUC HEK293T rose to 402,805±23,794, and
322,261±23,201, respectively, as compared to that of empty
vector transfected cells, 237,017±15,470 (Figure 6a). These
findings showed that overexpressed MT activates the
HIF–HRE pathway and may protect cells from hypoxic injury.
Iron chelation was not responsible for HIF induction by MT
Degradation of HIF requires prolyl hydroxylase which needs
iron as a cofactor. To investigate whether MT, a metal
chelating agent, might stabilize HIF by iron chelation, we
added abundant iron to the medium. We did not observe any
changes of MT-induced HRE-LUC activity in the presence of
excessive iron. These findings showed that iron chelation was
not responsible for HIF induction by MT under our
experimental conditions (Figure 6b).
MT activates the HIF–HRE system through the MEK/ERK
pathway
To elucidate a mechanism of activation of the HIF–HRE
systems by MT, we examined involvement of mammalian
Actin
MT
Day 7Day 3Sham
Day 3 (negative control)Day 7
Day 3Sham
Figure 2 | Immunohistochemical and Western blot analysis of
MT. In the sections of sham-operated kidneys, weak MT staining
was found in the cytoplasm and nuclei of some tubules (a). Three
days after the induction of chronic hypoxia, we found intense
staining of MT in proximal tubular cells in the cortex (b), and the
density was sustained in the cortex 7 days after the procedure (c).
Staining with the monoclonal antibody preincubated with MT in
sections of the experimental animals at day 3 confirmed specific
staining of MT (d). Magnification,  400. (e) Western blot analysis
demonstrated that MT was upregulated in the stenotic kidney.
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Figure 3 | Changes of MT by a proinflammatory factor or
oxidative stress. No changes in MT gene expression by addition
of TNF-a and hydrogen peroxide were observed. On the other
hand, zinc chloride, which is an inducer of MT, markedly
upregulated MT expression. *Po0.05 versus control.
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Figure 4 | MT activates the HIF–HRE pathway and its
downstream targets. (a) LUC activity in HRE-LUC was increased
by MT in a dose-dependent manner both in normoxic and
hypoxic conditions. *Po0.05 versus control. (b) MT upregulated
target genes of the HIF–HRE systems, such as VEGF, Glut-1, and
HO-1, both under normoxic (Nor) and hypoxic (Hyp) conditions.
*Po0.05 versus normoxic control. #Po0.05 versus hypoxic
control.
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target of rapamycin (mTOR). Rapamycin, mTOR inhibitor,
significantly reduced the LUC activity increased by MT
stimulation (Figure 7a). These concentrations of rapamycin
did not have any influence on cell viability by the lactate
dehydrogenase assay (data not shown). MT did not
phosphorylate Akt (Figure 7b), which suggested that the
PI3K/Akt pathway, at the upstream of mTOR, was not
involved in the activation of the HRE–HIF pathway by MT.
Next, we investigated a function of the mitogen-activated
protein kinase/ERK kinase (MEK)/ERK pathway. U0126,
MEK inhibitor, significantly reduced the LUC activity
increased by MT stimulation (Figure 7c) in both normoxic
and hypoxic conditions. Furthermore, as shown in Figure 7d,
MT phosphorylated ERK without affecting total ERK. Our
findings of phosphorylation of ERK by MT and blunting of
the HIF–HRE pathway by inhibition of the MEK/ERK
pathway suggest that this pathway mediates activation of
the HIF–HRE system by MT.
DISCUSSION
In this study, we utilized cDNA microarray technology to
define global changes in renal gene expression during chronic
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Figure 5 | Quantitative real-time PCR analysis and western
blot analysis of HIF-1a. (a) Quantitative real-time PCR
demonstrated that mRNA levels of HIF-1a did not alter by MT
stimulation under normoxic condition as well as under hypoxic
condition. (b) Western blot analysis demonstrated that MT
stimulation increased the HIF-1a protein under the normoxic
condition as well as under the hypoxic condition.
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Figure 6 | MT activates the HIF–HRE pathway in an iron-
chelation independent manner. (a) MT-overexpression study:
LUC activity of HRE-LUC HEK293T, transiently transfected with a
vector plasmid of hMT-1 (MT-1OE) or hMT-2 (MT-2OE), rose
significantly as compared to that of cells transfected with empty
vector (control). *Po0.05 versus control. (b) Abundant supply of
iron to the medium with MT did not reduce the LUC activity of
HRE-LUC under normoxia. *Po0.05 versus control.
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Figure 7 | MT activates the HIF–HRE systems via the MEK/ERK
pathway, but not the PI3K/Akt pathway. (a) Rapamycin
significantly blunted the increased LUC activity by MT. *Po0.05
versus control treated with MT at the corresponding
concentrations. (b) Western blot analysis demonstrated that MT
did not affect phosphorylation of Akt at any time points after MT
stimulation (1250 nM) in normoxic and hypoxic conditions. (c)
U0126, MEK inhibitor, significantly blunted the increased LUC
activity by MT. *Po0.05 versus control treated with MT at the
corresponding concentrations. (d) Western blot analysis
demonstrated that MT phosphorylated ERK at 30 and 120 min
after MT stimulation (1250 nM) in both normoxic and hypoxic
conditions.
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hypoxia of the kidney. Microarray-based analysis identified a
broad range of genes whose mRNA levels are altered in
response to chronic hypoxia of the kidney, including known
genes previously implicated in the pathogenesis of acute
ischemia/reperfusion injury (for example, KIM-1). Micro-
array technology has been applied to an acute ischemia
model of the kidney13–17 as well as to acute ischemia of
culture tubular cells,18 but according to our knowledge, this is
the first study with this technology focusing on chronic
hypoxia of the kidney.
To clarify a molecular pathomechanism of chronic
hypoxia, we employed a model of chronic renal artery
stenosis, because this model is not confounded by factors
such as proteinuria and hyperglycemia. Although this model
is known as 2K1C and has been used in studies on
hypertension, it has also been used to study chronic renal
ischemia. Histological changes observed in this study were
consistent with previous reports,19 and we confirmed chronic
hypoxia at these time points using hypoxia-sensing rat
carrying the HRE-driven tagged luciferase gene in our
previous report.20 Although we excluded obviously necrotic
samples from our analysis, we cannot ignore possible
contributions of inflammatory changes or apoptosis to MT
expression in the stenotic kidney.
The deletorious responses of renal cells to a hypoxic insult
include transdifferentiation,21 cell death,22–24 production of
extracellular matrix,25,26 and so on. Our studies demon-
strated that chronic hypoxia induced changes of expression of
a variety of classes of genes, including growth factors, kinases,
poteases and protease inhibitors, adhesion molecules, and
other genes. Our quantitative real-time PCR analysis
validated the results of microarray studies. Among these,
we focused on MT.
MT is a low molecular weight, cystein-rich, and highly
inducible protein. MT binds heavy metal (zinc, copper,
selenium, and so on) with high affinity through the thiol
group of its cysteine residues, and it is involved in metal
detoxification. MT also functions as a scavenger of free
radicals due to its many cystein residues. MT gene expression
is induced by a variety of stimuli, such as metal exposure,
oxidative stress, glucocorticoids, and also hypoxia.27 In
mammals, four major subfamilies exist (MT-1, -2, -3, -4),
of which MT-1 and MT-2 are the most widely expressed
isoforms in the body. In humans, the known functional MT-1
and MT-2 isoforms are MT-1A, B, E, F, G, H, X, and MT-2A.
However, to date, a specific function, regulation, and
expression of each isoform remains to be elucidated.28
We observed upregulation of MT in proximal tubules of
the chronically hypoxic kidney. Previous studies identified
MT in the cytoplasm and nuclei of a proximal tubules, which
were upregulated by copper injection29 or, in addition, in
distal tubules and parietal wall of Bowman’s capsule by
exposure to gasoline.30 We, for the first time, demonstrated
upregulation of MT in the kidney by hypoxia, although
upregulation of MT by a decrease in oxygen tensions has
been observed in cancer cells.31 The degree of upregulation of
MT by hypoxia in vivo was much more than that in cultured
tubular cells. This may be due to enhanced MT expression by
other factors such as oxidative stress32 in addition to a
decrease in oxygen tensions.
MT protects cells as an antioxidant. Previous studies
reported that MT protects islets,33 hearts,34,35 cardiomyo-
cytes36 from hypoxia, and the protective mechanism includes
antiapoptotic effects by scavenging most reactive oxygen
species.35 In this study, we demonstrated that MT protects
the kidney against hypoxia through another novel mechan-
ism, stabilization of HIF. We confirmed upregulation of HIF
by two independent studies, stimulation of cultured cells by
addition of MT in the culture media and by transient
transfection of MT-expressing vectors. A previous report
showed that MT at the concentrations we employed in this
study does not have any influences on cell viability,37 and we
confirmed lack of toxicity of MT by the lactate dehydrogenase
assay. HIF is a master switch of defensive mechanisms against
hypoxia and is known to be regulated mainly at the
degradation step of the protein.38,39 Our observations are
further supported by a recent finding by Feng et al.,40 who
reported that MT-overexpression increased HIF-1a protein
level in cardiomyocytes under diabetic conditions. Although
it is still a matter of debate, some studies demonstrated that
oxidative stress suppresses the HIF–HRE pathway.41–44
Scavenging of ROS by MT33 may, at least in part, has a
function in upregulation of HIF under hypoxic conditions
which are known to be associated oxidative stress, although
this mechanism is unlikely in normoxia. MT is a metal-
binding protein with zinc as a major substrate. Thus,
theoretically MT may inactivate factor inhibiting HIF by
providing zinc with a subsequent increase in HIF expression
at the mRNA level.45 However, this was not the mechanism of
HIF activation by MT as we did not observe any changes of
HIF mRNA levels. Our studies showed that upregulation of
HIF-1a by MT was likely due to stabilization of the protein.
We speculated that extracellular MT may stabilize HIF at
the protein level and investigated which signal transduction
pathway was responsible. MT may activate an intracellular
signaling pathway by binding to its receptor.46 Otherwise,
MT may be taken up into tubular cells by endocytosis with a
subsequent stimulation of an intracellular signaling cas-
cade.47,48 A number of studies suggested that the PI3K/Akt/
mTOR pathway and/or the MEK/ERK pathway are involved
in activation of the HIF/HRE system in addition to hypoxic
stimuli.49–51 These observations were further confirmed by
transfection of a constitutively active or dominant-negative
form of Akt,52 and also of a constitutive active form of MEK-
249 into cancer cells. As we observed that rapamycin
significantly reduced the LUC activity induced by MT
stimulation, we first focused attention on the receptor
tyrosine kinase (RTK)/PI3K/Akt pathway, upstream of
mTOR. However, MT stimulation did not phosphorylate
Akt, which suggested that MT regulated steps leading to
mTOR independently of RTK/PI3K. Although these results
do not exclude a possible contribution of receptor tyrosine
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kinases to activation of the HIF/HRE pathway which is likely
to occur through multiple mechanisms in the stenotic kidney
in vivo, we next investigated a contribution of ERK to
activation of the HIF/HRE pathway by MT.
MT phosphorylates ERK possibly by release of zinc by
stimuli such as oxidative stress,53 and the function of
phosphorylation by the MEK/ERK pathway in the stabiliza-
tion of HIF-1a transactivity by facilatating the interaction
between p300 and HIF-1a has also been demonstrated under
normoxic conditions49,51,54 as well as under the hypoxic
conditions.55 Therefore, we studied a function of the MEK/
ERK pathway in stimulation of the HIF–HRE pathway by MT.
Our data demonstrated that inhibition of MEK/ERK
activation by U0126 blunted the activation of the HIF–HRE
pathway by MT. Thus, MT stimulated the MEK/ERK
pathway, leading to stimulation of mTOR and subsequent
stabilization of HIF at the protein level in our studies.
Induction of HIF by MT seems to be more prominent under
hypoxia than under normoxia. Li et al.55 reported that
phosphorylated ERK was temporally upregulated ahead of
HIF-1a protein in developing rat brain after bilateral carotid
artery ligation. We suppose that hypoxia exhibits the synergic
effect on phosphorylating ERK by MT, followed by activation
of HIF.
In conclusion, using DNA microarray we have identified
131 genes that increase in mRNA expression and 55 genes
that decrease in the course of chronic hypoxia. Among these,
we focused on antioxidants, MT. We confirmed upregulation
of MT by real-time quantitative PCR as well as immuno-
histochemical analysis. Furthermore, we demonstrated that
MT activates the HIF–HRE pathway by stimulation of the
MEK/ERK/mTOR pathway. Induction of MT by hypoxia may
protect organs against by the novel mechansim, that is
stabilization of HIF.
MATERIALS AND METHODS
Experimental animals and induction of chronic hypoxia in the
kidney
Male Sprague–Dawley rats (Nippon Seibutsu Zairyo Center Co.,
Saitama, Japan) at the age of 8 weeks were used in this study. All rats
were housed in a specific pathogen-free facility and were confirmed
to be negative for common viral pathogens by routine sera analyses.
All experiments were conducted in accordance with the Guide for
Animal Experimentation at the University of Tokyo. Chronic
hypoxia of the kidney was induced as previously described.20
Briefly, a U-shaped silver clip (0.23 mm internal diameter) was
placed around the left renal artery, and at 3 days or 7 days after the
procedure kidneys were harvested for analysis described below.
High-density oligonucleotide microarray analysis
Total RNA from cortical tissues from each rat was isolated with
ISOGEN (Nippon Gene, Tokyo, Japan) according to the manufac-
turer’s instructions. The Affymetrix Rat 230A oligonucleotide array
sets (Affymetrix, Santa Clara, CA, USA), which contain 15,924
probe sets, were used to compare gene expression profiles of
baseline, 3- and 7-day-group rats according to the manufacturer’s
instructions. Briefly, biotinylated cRNAs were synthesized and
hybridized to the GeneChip probe arrays, which were then washed
in washing solution, stained with streptavidin–phycoerythrin, and
scanned. The data obtained were analyzed with Affymetrix
Microarray Suite v5.0. All time points were microarrayed as
experimental duplicate.
Cell culture
IRPTCs (a generous gift from Dr Julie R. Ingelfinger, MGH, Boston,
MA, USA) and HRE-LUC stably transfected IRPTCs were cultured
under the previously described conditions.56 Stable transfectants of
HEK293T expressing HRE-driven luciferase were selected by
geneticin and were cultured in Dulbecco’s modified Eagle’s medium
(Nissui, Tokyo, Japan) supplemented with 10% fetal bovine serum
(JRH Biosciences, Lenexa, KS, USA), 50 U/ml penicillin, 50 mg/ml
streptomycin. The cells were grown at 37 1C under a humidified
atmosphere of 5% CO2/95% air. Hypoxia was provided by exposure
to 1% O2/5% CO2 with the balance as nitrogen in a multigas
incubator, APM-30D (ASTEC, Fukuoka, Japan). Stimulation by
hypoxia, zinc chloride at 33.3 mM, hydrogen peroxide at 100 mM
(Wako, Tokyo, Japan) or TNF-a at 10 ng/ml (R&D Systems,
Minneapolis, MN, USA) was initiated at 70% confluence. Cells
were treated by the addition of MT-I (Sigma-Aldrich, St. Louis, MO,
USA), with and without iron(II) sulfite (Wako), rapamycin at 50 nM
(Sigma-Aldrich), or U0126 at 3 mM (Cell Signaling, Danvers, MA,
USA) in a serum free condition for 24 h, followed by measurement
of LUC activity of the cell lysate.
Real-time quantitative RT-PCR
Total RNA from cortical tissues from each rat or IRPTC was isolated
utilizing ISOGEN, and was reverse-transcribed with Im-Prom II
reverse transcription kit (Promega, Madison, WI, USA). cDNA
(1mg) was subjected to real-time RT-PCR (iCycler iQ; Bio-Rad,
Hercules, CA, USA) utilizing SYBR Green Supermix. The relative
amounts of genes were calculated with calibration using expression
levels of b-actin. Corresponding primers have been described in the
literature57,58 except for ANGPTL 4: 50-ATC CCC AAG GCG AGT
TCT GG-30, 50-TGT CCT CAC CCC CCA AAT GG-30; ceruloplas-
min: 50-GCA AGG GGC AGT TTG AAG ATG-30, 50-CAC CTG TTC
TCT GAA TGT GCT GTC-30; KIM-1: 50-CCA CCT CTA CTC CAA
CAC CAG AAC-30, 50- GAT GTC ACA GTG CCA TTC CAG TC-3;
NGAL: 50-CGT CAC TTC CAT CCT CGT CAG G-30, 50-ATC GGA
CAG CCC CTT GGT TC-30; IGFBP1: 50-ATG GAA GGA GCC CTG
CCA AC-30, 50-ATG TCT CGC ACT GTT TGC TGT G-30; HIF-1a:
50-GTT TAC TAA AGG ACA AGT CAC C-30, 50-TTC TGT TTG
TTG AAG GGA G-30. Ratios for each product/b-actin were
calculated for each sample and expressed as the mean±s.e.m.
Immunohistochemistry
For MT staining, methyl Carnoy’s-fixed, paraffin-embedded sections
(3mm) were probed with anti-MT (1/100; Zymed, Carlsbad, CA,
USA), biotinylated anti-mouse IgG (1/400; Vector Laboratories,
Burlingame, CA, USA) and HRP-avidin. The slides were then
developed with diaminobenzidine (Wako), followed by counter
staining with methyl green. Specificity of the antibody was further
examined by an absorption test of the antibody with MT in
immunohistochemical analysis.
Western blotting analyses
Whole proteins for analysis of MT and actin were prepared using
NP-40 lysis buffer (150 mmol/l NaCl, 1% NP-40, and 50 mmol/l
Tris-HCl, pH 8.0). Nuclear extracts for analysis of HIF-1a were
prepared from cultured cells using a nuclear extraction kit (Pierce,
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Rockford, IL, USA). Aliquots of protein were resolved by
SDS–polyacrylamide gel electrophoresis under reducing conditions
and transferred onto PVDF membranes. The membranes were
incubated with anti-MT (1/200; Stressgen Bioreagents, Ann Arbor,
MI, USA), polyclonal anti-actin (1/1000; Sigma-Aldrich), anti-
phospho-Akt, anti-phospho-ERK, anti-ERK (1/1000; Cell Signal-
ing), or anti-HIF-1a (Novus Biologic, Littleton, CO, USA). Specific
bands were visualized with AP-conjugated secondary antibody and
BCIP/NBT (Sigma-Aldrich) or HRP-conjugated secondary antibody
and the ECL plus kit (Amersham Biosciences, Buckinghamshire,
UK). Density of bands was analyzed using Image J version 1.34 s
software (National Institutes of Health, Bethesda, MD, USA).
Transfection of MT-overexpressing vectors
An open reading frame coding for the human MTs (hMTs) was
obtained by RT–PCR using total RNA of human renal proximal
tubule epithelial cells (Lonza, Walkersville, MD, USA) as a template.
Primers used were forward: GAA ATG GAC CCC AAC TGC TCC
TGC-30, reverse: 50-TCA GGC ACA GCA GCT GCA CTT CTC-30 for
MT-1 and forward: 50-GCC ATG GAT CCC AAC TGC TCC TGC-30,
reverse: 50-GGA GCG GGG CTG TCC CAG CAT CAG-30 for MT-2,
respectively. The PCR fragments of 186 nt for human MT-1E (hMT-
1) and 206 nt for human MT-2A (hMT-2) were subcloned into
pGMT-T Easy (Promega) and was processed to dideoxy-DNA
sequencing. The sequence-confirmed fragment was digested with
ApaI and PstI and again incorporated to the mammalian expression
vector, pcDNA4/TO/myc-HisA (Invitrogen, Carlsbad, CA, USA).
Then, the vector plasmids (pcDNA-hMT-1 and hMT-2) were
transiently transfected to HEK293T, which stably expressed HRE-
driven luciferase, using Lipofectamine reagent (Invitrogen) accord-
ing to the manufacturer’s protocol. At 36 h after transfection, cell
lysate was collected for evaluation of LUC activity.
Statistical analysis
Values were presented as mean±s.e.m. One-way analysis of variance
followed by the least significant difference method was used to
determine differences more than two groups for all continuous
parameters, whereas Student’s t-test was used for two-group data.
The significance level was set at Po0.05 for all tests (SPSS for
Windows 11.0) (SPSS Inc., Chicago, IL, USA).
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